Inhibitor Therapeutics (INTI) Preferred Dividend Payments (2018 - 2022)
Inhibitor Therapeutics' (INTI) quarterly Preferred Dividend Payments came in at $39452.0 in Q4 2022, down 21.74% YoY from $50411.0 in Q4 2021, and down 21.74% on a QoQ basis from $50411.0 in Q3 2022.
Inhibitor Therapeutics (INTI) Preferred Dividend Payments (2018 - 2022) Analysis & Trends
Inhibitor Therapeutics (INTI) has 5 years of Preferred Dividend Payments data on file, last reported at $39452.0 in Q4 2022.
- Quarterly Preferred Dividend Payments fell 21.74% year-over-year to $39452.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $189041.0 (down 5.48% YoY) and the FY2022 annual result came in at $189042.0, down 5.48% from the prior year.
- Preferred Dividend Payments retreated to $39452.0 in Q4 2022, from $50411.0 in the prior quarter.
- In the past five years, Preferred Dividend Payments ranged from a high of $50412.0 in Q4 2019 to a low of $26630.0 in Q1 2018.
- A 5-year average of $47304.2 and a median of $49863.0 in 2019 frame the typical range for Preferred Dividend Payments.
- Annual changes were most pronounced in 2019 — Preferred Dividend Payments surged 85.19% — and 2022, when it retreated 21.74%.
- Tracing INTI's Preferred Dividend Payments over 5 years: stood at $50411.0 in 2018, then climbed by 0.0% to $50412.0 in 2019, then slipped by 0.0% to $50411.0 in 2020, then changed by 0.0% to $50411.0 in 2021, then retreated by 21.74% to $39452.0 in 2022.
- The last three Preferred Dividend Payments figures came in at $39452.0 (Q4 2022), $50411.0 (Q3 2022), and $49863.0 (Q2 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 39,452.00 |
| Sep 30, 2022 | 50,411.00 |
| Jun 30, 2022 | 49,863.00 |
| Mar 31, 2022 | 49,315.00 |
| Dec 31, 2021 | 50,411.00 |
| Sep 30, 2021 | 50,412.00 |
| Jun 30, 2021 | 49,863.00 |
| Mar 31, 2021 | 49,315.00 |
| Dec 31, 2020 | 50,411.00 |
| Sep 30, 2020 | 50,411.00 |
| Jun 30, 2020 | 49,863.00 |
| Mar 31, 2020 | 49,863.00 |
| Dec 31, 2019 | 50,412.00 |
| Sep 30, 2019 | 50,410.00 |
| Jun 30, 2019 | 49,863.00 |
| Mar 31, 2019 | 49,315.00 |
| Dec 31, 2018 | 50,411.00 |
| Sep 30, 2018 | 49,534.00 |
| Jun 30, 2018 | 29,918.00 |
| Mar 31, 2018 | 26,630.00 |